MGVS clinical research program is focused on areas of unmet needs in cardiovascular disease.
MGVS is committed to transparency in medical research. We have registered our active company-sponsored clinical trials on the National Institutes of Health clinical trial database. www.clinicaltrials.gov
MGVS had completed enrollment and treatment of 35 patients in two phase I/II studies of MultiGeneAngio for PAD between February 2007 and August 2011. The first study was conducted in two leading medical centers in the USA (the University of Michigan and the University of Pennsylvania) and included 12 patients with severe claudication. The second study was conducted in seven leading medical centers in Israel, and included 23 patients with chronic critical limb ischemia (a more advanced stage of peripheral arterial disease). Both studies demonstrated product safety and promising clinical efficacy for patients who failed or were found unsuitable for current therapies.